. 2023 Jul 8;402(10396):129-140.

doi: 10.1016/S0140-6736(23)00731-6. Epub 2023 Jun 20.

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

Monica S Thakar¹, Brent R Logan², Jennifer M Puck³, Elizabeth A Dunn⁴, Rebecca H Buckley⁵, Morton J Cowan³, Richard J O'Reilly⁶, Neena Kapoor⁷, Lisa Forbes Satter⁸, Sung-Yun Pai⁹, Jennifer Heimall¹⁰, Sharat Chandra¹¹, Christen L Ebens¹², Deepak Chellapandian¹³, Olatundun Williams¹⁴, Lauri M Burroughs¹⁵, Blachy Davila Saldana¹⁶, Ahmad Rayes¹⁷, Lisa M Madden¹⁸, Shanmuganathan Chandrakasan¹⁹, Jeffrey J Bednarski 2nd²⁰, Kenneth B DeSantes²¹, Geoffrey D E Cuvelier²², Pierre Teira²³, Alfred P Gillio²⁴, Hesham Eissa²⁵, Alan P Knutsen²⁶, Frederick D Goldman²⁷, Victor M Aquino²⁸, Evan B Shereck²⁹, Theodore B Moore³⁰, Emi H Caywood³¹, Mark T Vander Lugt³², Jacob Rozmus³³, Larisa Broglie³⁴, Lolie C Yu³⁵, Ami J Shah³⁶, Jeffrey R Andolina³⁷, Xuerong Liu³⁸, Roberta E Parrott⁵, Jasmeen Dara³, Susan Prockop³⁹, Caridad A Martinez⁸, Malika Kapadia³⁹, Soma C Jyonouchi¹⁰, Kathleen E Sullivan¹⁰, Jack J Bleesing¹¹, Sonali Chaudhury⁴⁰, Aleksandra Petrovic¹⁵, Michael D Keller⁴¹, Troy C Quigg⁴², Suhag Parikh¹⁹, Shalini Shenoy²⁰, Christine Seroogy⁴³, Tamar Rubin⁴⁴, Hélène Decaluwe²³, John M Routes⁴⁵, Troy R Torgerson⁴⁶, Jennifer W Leiding⁴⁷, Michael A Pulsipher¹⁷, Donald B Kohn³⁰, Linda M Griffith⁴⁸, Elie Haddad²³, Christopher C Dvorak³, Luigi D Notarangelo⁴⁹

Affiliations

¹ Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. Electronic address: msthakar@fredhutch.org.
² Division of Biostatistics, Medical College of Wisconsin, WI, USA; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
³ Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, University of California San Francisco, CA, USA; UCSF Benioff Children's Hospital, San Francisco, CA, USA.
⁴ Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, University of California San Francisco, CA, USA.
⁵ Department of Allergy and Immunology, Department of Pediatrics and Immunology, Duke University Medical Center, Durham, NC, USA.
⁶ Stem Cell Transplantation and Cellular Therapy, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Transplant and Cell Therapy Program and Laboratory, Department of Pediatrics, Keck School of Medicine, University of Southern California, CA, USA; Hematology, Oncology and TCT, Children's Hospital Los Angeles, Los Angeles, CA, USA.
⁸ Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Immunology Allergy and Retrovirology, Center for Human Immunobiology, Texas Children's Hospital Infusion Center, Houston, TX, USA.
⁹ Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute (NCI)/NIH, Bethesda, MD, USA.
¹⁰ Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, PA, USA; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹¹ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
¹² Department of Pediatrics, Division of Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN, USA.
¹³ Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Cell and Gene Therapy for Nonmalignant Conditions, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.
¹⁴ Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA.
¹⁵ Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
¹⁶ Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington DC, USA; Division of Blood and Marrow Transplantation and Center for Cancer and Immunology Research, Children's National Hospital, Washington DC, USA.
¹⁷ Pediatric Immunology and Blood and Marrow Transplant Program, University of Utah, Salt Lake City, UT, USA; Intermountain Primary Children's Hospital, Salt Lake City, UT, USA.
¹⁸ Pediatric Bone Marrow Transplant Program, Texas Transplant Institute, San Antonio, TX, USA.
¹⁹ Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
²⁰ Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
²¹ Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
²² University of Manitoba, Winnipeg, MB, Canada; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, MB, Canada.
²³ Department of Pediatrics and Department of Microbiology, Immunology and Infectious Diseases, University of Montreal, Montreal, QC, Canada; Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.
²⁴ Pediatric Stem Cell and Cellular Therapy Division, Joseph M Sanzari Children's Hospital at HMH Hackensack University Medical Center, Hackensack, NJ, USA.
²⁵ Department of Pediatrics, University of Colorado, Aurora, CO, USA; Bone Marrow Transplant and Cellular Therapeutics, Children's Hospital of Colorado, Aurora, CO, USA.
²⁶ Pediatric Allergy and Immunology, St Louis University, St Louis, MO, USA; Jeffrey Modell Diagnostic & Research Center for Primary Immunodeficiencies, Cardinal Glennon Children's Hospital, St Louis, MO, USA.
²⁷ Division of Hematology/Oncology/BMT, Department of Pediatrics, University of Alabama, Birmingham, AL, USA.
²⁸ Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
²⁹ Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
³⁰ Pediatric Blood and Marrow Transplant Program, Division of Pediatric Hematology/Oncology in the Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.
³¹ Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Nemours Children's Health, Delaware, Wilmington, DE, USA.
³² Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
³³ Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital, Vancouver, BC, Canada.
³⁴ Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
³⁵ Louisiana State University Health New Orleans School of Medicine, New Orleans, LA, USA; Children's Hospital of New Orleans, New Orleans, LA, USA.
³⁶ Division of Hematology/Oncology/Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Palo Alto, CA, USA.
³⁷ Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY, USA.
³⁸ Division of Biostatistics, Medical College of Wisconsin, WI, USA.
³⁹ Department of Pediatrics, Harvard University Medical School, Boston, MA, USA; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
⁴⁰ Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
⁴¹ Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington DC, USA; Division of Blood and Marrow Transplantation and Center for Cancer and Immunology Research, Children's National Hospital, Washington DC, USA; Intermountain Primary Children's Hospital, Salt Lake City, UT, USA.
⁴² Pediatrics, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Pediatric Blood and Marrow Transplant and Cellular Therapy Program, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
⁴³ Division of Allergy, Immunology, and Rheumatology, University of Wisconsin, Madison, WI, USA.
⁴⁴ Division of Pediatric Allergy and Immunology, University of Manitoba, Winnipeg, MB, Canada.
⁴⁵ Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴⁶ Experimental Immunology, Allen Institute for Immunology, Seattle, WA, USA.
⁴⁷ Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
⁴⁸ Division of Allergy, Immunology and Transplantation, (NIAID)/NIH, Bethesda, MD, USA.
⁴⁹ Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID)/NIH, Bethesda, MD, USA.

PMID: 37352885
PMCID: PMC10386791
DOI: 10.1016/S0140-6736(23)00731-6

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

Monica S Thakar et al. Lancet. 2023.

. 2023 Jul 8;402(10396):129-140.

doi: 10.1016/S0140-6736(23)00731-6. Epub 2023 Jun 20.

Authors

Affiliations

¹ Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. Electronic address: msthakar@fredhutch.org.
² Division of Biostatistics, Medical College of Wisconsin, WI, USA; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
³ Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, University of California San Francisco, CA, USA; UCSF Benioff Children's Hospital, San Francisco, CA, USA.
⁴ Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, University of California San Francisco, CA, USA.
⁵ Department of Allergy and Immunology, Department of Pediatrics and Immunology, Duke University Medical Center, Durham, NC, USA.
⁶ Stem Cell Transplantation and Cellular Therapy, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Transplant and Cell Therapy Program and Laboratory, Department of Pediatrics, Keck School of Medicine, University of Southern California, CA, USA; Hematology, Oncology and TCT, Children's Hospital Los Angeles, Los Angeles, CA, USA.
⁸ Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Immunology Allergy and Retrovirology, Center for Human Immunobiology, Texas Children's Hospital Infusion Center, Houston, TX, USA.
⁹ Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute (NCI)/NIH, Bethesda, MD, USA.
¹⁰ Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, PA, USA; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹¹ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
¹² Department of Pediatrics, Division of Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN, USA.
¹³ Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Cell and Gene Therapy for Nonmalignant Conditions, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.
¹⁴ Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA.
¹⁵ Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
¹⁶ Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington DC, USA; Division of Blood and Marrow Transplantation and Center for Cancer and Immunology Research, Children's National Hospital, Washington DC, USA.
¹⁷ Pediatric Immunology and Blood and Marrow Transplant Program, University of Utah, Salt Lake City, UT, USA; Intermountain Primary Children's Hospital, Salt Lake City, UT, USA.
¹⁸ Pediatric Bone Marrow Transplant Program, Texas Transplant Institute, San Antonio, TX, USA.
¹⁹ Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
²⁰ Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
²¹ Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
²² University of Manitoba, Winnipeg, MB, Canada; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, MB, Canada.
²³ Department of Pediatrics and Department of Microbiology, Immunology and Infectious Diseases, University of Montreal, Montreal, QC, Canada; Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.
²⁴ Pediatric Stem Cell and Cellular Therapy Division, Joseph M Sanzari Children's Hospital at HMH Hackensack University Medical Center, Hackensack, NJ, USA.
²⁵ Department of Pediatrics, University of Colorado, Aurora, CO, USA; Bone Marrow Transplant and Cellular Therapeutics, Children's Hospital of Colorado, Aurora, CO, USA.
²⁶ Pediatric Allergy and Immunology, St Louis University, St Louis, MO, USA; Jeffrey Modell Diagnostic & Research Center for Primary Immunodeficiencies, Cardinal Glennon Children's Hospital, St Louis, MO, USA.
²⁷ Division of Hematology/Oncology/BMT, Department of Pediatrics, University of Alabama, Birmingham, AL, USA.
²⁸ Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
²⁹ Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
³⁰ Pediatric Blood and Marrow Transplant Program, Division of Pediatric Hematology/Oncology in the Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.
³¹ Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Nemours Children's Health, Delaware, Wilmington, DE, USA.
³² Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
³³ Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; British Columbia Children's Hospital, Vancouver, BC, Canada.
³⁴ Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
³⁵ Louisiana State University Health New Orleans School of Medicine, New Orleans, LA, USA; Children's Hospital of New Orleans, New Orleans, LA, USA.
³⁶ Division of Hematology/Oncology/Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Palo Alto, CA, USA.
³⁷ Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY, USA.
³⁸ Division of Biostatistics, Medical College of Wisconsin, WI, USA.
³⁹ Department of Pediatrics, Harvard University Medical School, Boston, MA, USA; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
⁴⁰ Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
⁴¹ Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington DC, USA; Division of Blood and Marrow Transplantation and Center for Cancer and Immunology Research, Children's National Hospital, Washington DC, USA; Intermountain Primary Children's Hospital, Salt Lake City, UT, USA.
⁴² Pediatrics, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Pediatric Blood and Marrow Transplant and Cellular Therapy Program, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
⁴³ Division of Allergy, Immunology, and Rheumatology, University of Wisconsin, Madison, WI, USA.
⁴⁴ Division of Pediatric Allergy and Immunology, University of Manitoba, Winnipeg, MB, Canada.
⁴⁵ Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴⁶ Experimental Immunology, Allen Institute for Immunology, Seattle, WA, USA.
⁴⁷ Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
⁴⁸ Division of Allergy, Immunology and Transplantation, (NIAID)/NIH, Bethesda, MD, USA.
⁴⁹ Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID)/NIH, Bethesda, MD, USA.

PMID: 37352885
PMCID: PMC10386791
DOI: 10.1016/S0140-6736(23)00731-6

Abstract

Background: Severe combined immunodeficiency (SCID) is fatal unless durable adaptive immunity is established, most commonly through allogeneic haematopoietic cell transplantation (HCT). The Primary Immune Deficiency Treatment Consortium (PIDTC) explored factors affecting the survival of individuals with SCID over almost four decades, focusing on the effects of population-based newborn screening for SCID that was initiated in 2008 and expanded during 2010-18.

Methods: We analysed transplantation-related data from children with SCID treated at 34 PIDTC sites in the USA and Canada, using the calendar time intervals 1982-89, 1990-99, 2000-09, and 2010-18. Categorical variables were compared by χ² test and continuous outcomes by the Kruskal-Wallis test. Overall survival was estimated by the Kaplan-Meier method. A multivariable analysis using Cox proportional hazards regression models examined risk factors for HCT outcomes, including the variables of time interval of HCT, infection status and age at HCT, trigger for diagnosis, SCID type and genotype, race and ethnicity of the patient, non-HLA-matched sibling donor type, graft type, GVHD prophylaxis, and conditioning intensity.

Findings: For 902 children with confirmed SCID, 5-year overall survival remained unchanged at 72%-73% for 28 years until 2010-18, when it increased to 87% (95% CI 82·1-90·6; n=268; p=0·0005). For children identified as having SCID by newborn screening since 2010, 5-year overall survival was 92·5% (95% CI 85·8-96·1), better than that of children identified by clinical illness or family history in the same interval (79·9% [69·5-87·0] and 85·4% [71·8-92·8], respectively [p=0·043]). Multivariable analysis demonstrated that the factors of active infection (hazard ratio [HR] 2·41, 95% CI 1·56-3·72; p<0·0001), age 3·5 months or older at HCT (2·12, 1·38-3·24; p=0·001), Black or African-American race (2·33, 1·56-3·46; p<0·0001), and certain SCID genotypes to be associated with lower overall survival during all time intervals. Moreover, after adjusting for several factors in this multivariable analysis, HCT after 2010 no longer conveyed a survival advantage over earlier time intervals studied (HR 0·73, 95% CI 0·43-1·26; p=0·097). This indicated that younger age and freedom from infections at HCT, both directly driven by newborn screening, were the main drivers for recent improvement in overall survival.

Interpretation: Population-based newborn screening has facilitated the identification of infants with SCID early in life, in turn leading to prompt HCT while avoiding infections. Public health programmes worldwide can benefit from this definitive demonstration of the value of newborn screening for SCID.

Funding: National Institute of Allergy and Infectious Diseases, Office of Rare Diseases Research, and National Center for Advancing Translational Sciences.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MST is a member of the Scientific Advisory Board for Proteios Technology. JMP has received royalties from Up-To-Date, and her spouse is employed by and owns stock in Invitae (a DNA sequencing company). MJC has received royalties from Up-to-Date and is on the scientific board of Homology Medicines, a gene therapy company, and is a data and safety monitoring board (DSMB) member for Bluebird Bio, Chiesi USA, and Rocket Pharmaceuticals. LFS is a member of the adjudication committee for Orchard Therapeutics and has received consulting fees from Takeda, CSL Behring, ADMA Biologics, Grifols, and Horizon. JH is on an Investigator-initiated grant at CSL Behring; is a consultant for ADMA, Horizon, and CIRM; and a clinical trial primary investigator (industry sponsored research) for Regeneron. LMB has received clinical trial support through the Fred Hutchinson Cancer Research Center by Medac including supply of treosulfan), is a member of the DSMB for clinical trials with Rocket Pharmaceuticals and Jasper Therapeutics, and has served on an advisory board for Horizon Therapeutics USA. BDS has undertaken ad-hoc consultancies for Sobi and Orchard Therapeutics. ShC is a member on the advisory board for SOBI. JJB is a member of an advisory board for Sobi and Horizon Therapeutics. GDEC has received consultancy fees from Miltenyi Biotech. FDG has received consultancy fees from GLG and Guidepoint Global, and is on the advisory board for Omerus. EBS is on the speaker's bureau for Sobi. EHC is an advisory board member for Pfizer. SP has received funding for the conduct of sponsored trials Atara Biotherapeutics, AlloVir, and Jasper Therapeutics and is on the advisory board for ADMA and Neovii; and is the inventor of IP Licensed to Atara with all rights assigned to Memorial Sloan Kettering Cancer Center. KES has served as a consultant for Enzyvant and the Immune Deficiency Foundation. AP is on the advisory boards for Orchard (MLD GT), Horizon, and Enzyvant, serves on the DSMB for ExCellTheraMK, and is a consultant for Enzyvant (2020). TCQ has been on the speaker's bureau and advisory board for Alexion Pharmaceuticals. SS is on the advisory board and provides consultancy for Graphite, Takeda, Janssen, Bristol Myers Squibb, data and safety monitoring committee for the National Heart, Lung, and Blood Institute (NHLBI), and Aruvant Sciences. HD was an advisor on an Eli Lilly Canada Scientific Advisory Board in April 2020. JWL in the past 12 months has been a speaker and consultant for Sobi; has been a speaker and consultant, and has received research funding from Horizon Therapeutics; has been a speaker, consultant, and on an advisory board for Pharming; has been a speaker and consultant for CSL Behring; is on the advisory board for ADMA Biologics; and is the site primary investigator for Therapure and a GreenCross employee and shareholder at Bluebird Bio. MAP has served on the advisory boards of Novartis, Medexus, Equillium, and Mesoblast; has received clinical study support from Adaptive and Miltenyi Biotech; and has received financial support for educational lectures for Miltenyi Biotech and Novartis. DBK is an inventor for the UC Regents on a lentiviral vector for gene therapy of ADA-SCID and is a member of the DSMB for Revcovi PEG-ADA (Chiesi USA). EH has received consultancy fees from JASPERS, Takeda, CSL-Behring, Octapharma, and Leadiant Biosciences. CCD is a member of the DSMB for Revcovi PEG-ADA and is a consultant for Orchard Therapeutics. All other authors declare no competing interests.

Figures

**Figure 1.. Overall Survival by Donor Source**
A, Entire cohort; B, matched sibling donors; C, matched other related and unrelated donors; and D, mismatched related donors. All donor sources other than HLA-matched siblings showed improvement in survival during 2010–2018. HLA-matched sibling transplantation showed superior survival throughout all time intervals.

**Figure 2.. Overall Survival 2010–2018, Based on Trigger for Diagnosis**
Survival was evaluated more closely during the time interval when NBS became available. The global significance of improved survival with NBS (P=0.043) was driven by differences between NBS and the clinical illness group (P=0.012) rather than differences in survival between NBS and FH (P=0.184). *Abbreviations:* FH, family history; NBS, newborn screening.

See this image and copyright information in PMC

Comment in

Newborn screening for severe combined immunodeficiency: changing the landscape of post-transplantation survival.
Barzaghi F, Aiuti A. Barzaghi F, et al. Lancet. 2023 Jul 8;402(10396):84-85. doi: 10.1016/S0140-6736(23)01057-7. Epub 2023 Jun 20. Lancet. 2023. PMID: 37352884 No abstract available.

Cited by

Thymic inborn errors of immunity.
Pala F, Notarangelo LD, Lionakis MS. Pala F, et al. J Allergy Clin Immunol. 2025 Feb;155(2):368-376. doi: 10.1016/j.jaci.2024.10.009. Epub 2024 Oct 18. J Allergy Clin Immunol. 2025. PMID: 39428079 Review.
Progress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity.
Arnold DE, Pai SY. Arnold DE, et al. Curr Opin Pediatr. 2023 Dec 1;35(6):663-670. doi: 10.1097/MOP.0000000000001292. Epub 2023 Sep 21. Curr Opin Pediatr. 2023. PMID: 37732933 Free PMC article. Review.
A Unique Comprehensive Model to Screen Newborns for Severe Combined Immunodeficiency-An Ontario Single-Centre Experience Spanning 2013-2023.
Al Ghamdi A, Pachul JW, Al Shaqaq A, Fraser M, Watts-Dickens A, Yang N, Vong L, Kim VHD, Siu VM, Pham-Huy A, Brager R, Reid B, Roifman CM. Al Ghamdi A, et al. Genes (Basel). 2024 Jul 15;15(7):920. doi: 10.3390/genes15070920. Genes (Basel). 2024. PMID: 39062699 Free PMC article.
Newborn Screening Followed By Early Treatment is Essential to Improve Survival in SCID.
Goebel GA, Cunha LAO, Minafra FG, Pinto JA. Goebel GA, et al. J Clin Immunol. 2025 May 15;45(1):94. doi: 10.1007/s10875-025-01887-x. J Clin Immunol. 2025. PMID: 40374985 Free PMC article.
Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide in patients with inborn errors of immunity: Experience in a reference center in Colombia.
Medina D, Castro JO, Castro DE, Beltrán E, Manzi E, Franco AA, Olaya M. Medina D, et al. Biomedica. 2024 Dec 23;44(Sp. 2):118-130. doi: 10.7705/biomedica.7560. Biomedica. 2024. PMID: 39836841 Free PMC article.

See all "Cited by" articles

References

1. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340(7): 508–16. - PubMed
1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet (London, England) 1968; 2(7583): 1366–9. - PubMed
1. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet 2003; 361(9357): 553–60. - PubMed
1. Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91(10): 3646–53. - PubMed
1. Dvorak CC, Long-Boyle J, Dara J, et al. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biol Blood Marrow Transplant 2019; 25(7): 1355–62. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

Affiliations

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials